Multinodular goiter (MNG) is a very common thyroid disorder determined by diverse goitrogenic factors, the most important one being iodine deficiency. The clinical presentation of a patient with MNG varies from a completely asymptomatic goiter to a life-threatening disease due to upper airway compression. Patients can develop underlying subclinical or overt hyperthyroidism due to autonomously hyperfunctioning nodules. In the absence of clinical, ultrasonographic, or cytological findings suggestive of malignancy, the best therapeutic approach for a patient with MNG will depend on the size and location of the goiter, the presence and severity of compressive symptoms, and the presence or absence of thyrotoxicosis. There is still no consensus regarding the treatment of atoxic MNGs. Hence, its optimal management remains controversial; possible therapies include levothyroxine (LT 4 ), surgery, and radioactive iodine ( 131 I). Suppressive treatment with LT 4 is discouraged due to the development of sub-clinical or overt hyperthyroidism and to its low efficacy when compared with surgery or 131 I. Total thyroidectomy is effective; however, it is associated with the risk of surgical complications and is often refused by the patient. 131 I therapy is an alternative to thyroid surgery to reduce the size of benign MNGs. Based on the ability of recombinant human TSH (rhTSH) to more than double thyroid 131 I uptake, this compound has been evaluated as an adjuvant to 131 I in the treatment of MNG. Very small doses of rhTSH have been used in patients with MNG and few safety concerns have been observed, but the ideal dose, both effective and safe, is yet to be defined.
Introduction
Radioactive iodine ( 131 I) was introduced almost three decades ago for the treatment of multinodular goiter (MNG) (1) . Since then, studies have demonstrated that 131 I is safe and effective (2, 3), leading to significant thyroid volume (TV) reduction, when compared with levothyroxine (LT 4 ) suppressive therapy. Overall, LT 4 suppressive therapy offers no benefit (4), particularly regarding the improvement in obstructive symptoms (such as dyspnea and dysphagia), to most patients (5, 6) . 131 I treatment reduces the MNG volume by w40% after 1 year and by 50-60% after 2-5 years (4, 5, 6, 7, 8, 9) . Nonetheless, the therapeutic efficacy of 131 I in patients with MNG depends to some extent on the 131 I uptake (RAIU). Frequently, MNGs have a low and heterogeneous RAIU, requiring high 131 I activities (10) .
The administration of recombinant human thyrotropin (rhTSH) before 131 I has been shown to be a potentially valuable therapeutic tool for the management of MNG (11, 12, 13, 14, 15, 16, 17, 18, 19, 20) . rhTSH in a low single dose increases 131 I uptake by two-to fourfold, and similar therapeutic effects (in comparison with higher 131 I activities without rhTSH prestimulation), and with lower exposure of extrathyroidal tissues to radiation (23 given (11, 14, 16, 19, 24, 25) . Overall, it has been shown that rhTSH doses lower than 0.1 mg do not cause acute increases in TV or thyroid hormone levels (26) . When given 24 h before the administration of fixed or calculated 131 I activities, rhTSH is a safe and efficacious adjunct therapeutic approach that allows for the administration of lower 131 I activities (24) .
Approach to the patient with MNG

Surgery
MNG is defined as the enlargement of the thyroid gland, in the absence of autoimmune thyroid disease, malignancy, or inflammation, and associated with more than one nodule identified clinically, ultrasonographically, or surgically. Factors that favor surgery as the treatment of choice include presence of symptoms or signs of compression within the neck, concern for co-existing thyroid cancer, substernal or retrosternal extension, or need for rapid correction of the thyrotoxic state (27) . Factors weighing against the choice of surgery include significant comorbidity such as cardiopulmonar disease, or other debilitating disorders. In other cases, the patient or patient's family refuse surgery.
Radioactive iodine
For more than seven decades, 131 (28) in most cases. Therefore, there was interest to explore strategies to enhance RAIU in these patients.
Recombinant human thyrotropin
The administration of a single, low dose of rhTSH considerably increased RAIU in patients with nodular goiter (21) . A dose of 0.01 mg rhTSH given 24 h before 131 I increased 24-h RAIU from 29 to 51%, while 0.03 mg rhTSH increased 24-h RAIU from 33 to 63% (21) . A single, low dose of rhTSH not only doubled 24-h RAIU, but also determined a more homogeneous distribution of 131 I within the thyroid gland in patients with nodular goiter, by stimulating 131 I uptake in relatively cold areas, more than in relatively hot areas (22) . It has been shown that pretreatment with a single, low dose of rhTSH allows for dose reduction of 131 I in patients with nodular goiter (31). 131 I therapy after pretreatment with a single, low dose of rhTSH in patients with nodular goiter resulted in TV reduction 1 year after therapy by 35% in the group pretreated with 0.01 mg rhTSH, and by 41% in the group pretreated with 0.03 mg rhTSH. This was accompanied by an increase in the smallest cross-sectional area of the tracheal lumen, by 17 and 44% respectively (31).
rhTSH and 131 I for MNG
In patients with toxic MNG (TMNG), medical management before 131 I therapy should be tailored based on the severity of the hyperthyroidism, patient's age, and comorbid conditions. Worsening of hyperthyroidism with increased heart rate, and rare cases of supraventricular tachycardia (including atrial fibrillation) have been observed in patients with TMNG or MNG treated with 131 I (32, 33) . Therefore, the use of b-blockers to prevent post-treatment tachyarrhythmias should be considered in all patients with TMNG who are older than 60 years of age and those with cardiovascular disease or severe
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www.eje-online.org hyperthyroidism (34) . Pretreatment with methimazole before 131 I therapy for TMNG is indicated in patients who are at an increased risk for complications due to worsening of hyperthyroidism, including elderly and those with cardiovascular disease or severe hyperthyroidism (35) . rhTSH can at least double thyroid RAIU (12, 18, 36, 37, 38) , depending on the baseline RAIU, and it determines a more homogeneous distribution of 131 I in MNG (22) . During the last decade, and based on the above observations, rhTSH has been evaluated as an adjuvant to 131 I therapy, in an attempt to improve the efficacy of this treatment for MNG (18, 39, 40) . Different rhTSH doses have been utilized: in some studies 0.2 mg or more (41, 42, 43, 44, 45, 46, 47) , while in others 0.1 mg or less (11, 16, 20, 24, 31, 48) . Since the introduction of rhTSH as an aid for 131 I therapy in MNG, nine randomized controlled trials (RCTs) have been published (11, 14, 15, 16, 19, 24, 25, 44, 45 reduction of the goiter. We were able to show a positive correlation between the radiation dose to the thyroid and the decrease in TV at 6 months ( Fig. 1) (12) . Approximately one-third of our patients receiving 0.2 mg rhTSH developed mild thyrotoxic symptoms controlled easily by the administration of a b-blocking agent (12) . In an attempt to lessen the adverse effects, the second study employed a single dose of 0.1 mg rhTSH (20) . All patients with low and heterogeneous RAIU developed increased and homogeneous RAIU (Fig. 2) (49) . TV was significantly reduced by 46.0G14.6% after 1 year; after 2 years, TV reduction was sustained in most patients (50) . A typical example of goiter shrinkage is shown in Fig. 3 (51) also demonstrated in a multicentric study that patients with baseline RAIU !20% achieved a greater reduction in the goiter size using modified-release rhTSH (MRrhTSH, an analog to rhTSH that is equipotent for increasing thyroid RAIU and that determines a lower peak plasma TSH concentration). MRrhTSH has an altered PK with a later T max than aqueous rhTSH. Potentially, MRrhTSH could reduce the side effects due to altered pharmacokinetics, with a delayed time to reach the maximum TSH concentration when compared with aqueous rhTSH (19) . Our third study compared two different rhTSH doses 
www.eje-online.org (0.005 and 0.1 mg) with one placebo group (16) followed by a fixed 30 mCi (1.11 GBq) activity. We demonstrated that a very low dose of 0.005 mg rhTSH was equally safe and effective as 0.1 mg rhTSH. Both doses increased the efficacy of 131 I (12). In a multicentric RCT, we compared two different MRrhTSH doses (0.01 and 0.03 mg) vs placebo (19) . The study showed that the threshold for efficacy seems to be w0.03 mg rhTSH, at which dose there are only few minor safety concerns (19) .
Side effects of rhTSH use in MNG
Sensation of thyroidal swelling can occur, but no acute compressive effects have been observed with 0.3 mg rhTSH (45) . In a selected group of patients with asymptomatic goiter (median volume of 40.0 ml), a 24% transient goiter volume increase was reported to occur 24 h after the administration of 0.3 mg rhTSH (45) . Adjunct therapies with very small doses of rhTSH (0.01-0.03 mg) have been evaluated in both euthyroid and hyperthyroid patients with MNG, and few safety concerns have been observed (19, 20) . However, one study showed that hyperthyroid patients had higher increases in thyroid hormone levels after 0.1 mg rhTSH plus 131 I, with a higher frequency of side effects (46) . Currently, the rhTSH adjunct therapy is not indicated in patients with TMNG (52) . In patients with critical tracheal narrowing, prophylactic glucocorticoid therapy should be considered to prevent rhTSH and 131 Irelated swelling and further respiratory compromise (52) . 
Concluding remarks
In patients with MNG, 131 I therapy preceded by rhTSH further enhances goiter volume shrinkage, compared with 131 I treatment alone. This effect has been demonstrated in short-and long-term studies, but it is still unknown as to which patients respond better to rhTSH. Currently, the lowest and most efficacious/effective dose of rhTSH is w0.03 mg. Studies comparing exogenous TSH with endogenous TSH are still required, in order to clarify the benefits and adverse effects of each type of treatment. It should be emphasized that rhTSH-stimulated 131 I therapy is still an off-label treatment for MNG.
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